Your Source for BioScience Venture Capital Data

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Comes from some other beginnings end.

Yes, this is the official final post for OnBioVC. Thank you for your readership. But, alas, I shall not go gentle into that good night. Rather, offered to you now is something more special, of greater value, contains tera-oodles of data, serves up a competitive intelligence lens like you have never before seen, and of course continues to deliver the company finance information you expect, all this and more is available to you now at Collective IP! Please observe additional details below…

Don’t wait! Sign up for the Collective IP blog now!

Don’t hesitate! Follow Collective IP on Twitter now!

Get smarter by signing up for a free Collective IP account now!


Follow me, Adam Rubenstein, on Twitter,

Connect with me on LinkedIn,

Read my personal blog,

Email me at:

It has been an honor serving the thousands of loyal and fanatical OnBioVC subscribers,

I appreciate you allowing me into your inbox!

I hope you will make the leap to Collective IP, you will not be disappointed…


Collective IP, Inc., the global leader in innovation intelligence, features the world’s most comprehensive and accurate organization of technologies residing in universities, companies and research institutes.

The Collective IP platform provides a novel search solution for business development professionals who focus on asset identification within companies and technology transfer organizations, and offers technology transfer and corporate licensing professionals a unique asset marketing platform.

Collective IP provides unrivaled access to licensing and acquisition opportunities around the globe, saving time and money for those engaged in the opportunity identification of time decaying assets, due diligence, competitive intelligence and intellectual property strategy.

And now … dramatic fade to Semisonic.

OptiMedica (Sunnyvale, CA), a commercial-stage medical device company focused on laser technology for cataract surgery, closed a $35M Series E financing. Participants include Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital.

iRhythm Technologies (San Francisco, CA), a commercial-stage medical device company that focused on cardiac rhythm monitoring, closed a $1.5M Series C financing. Participants include the California HealthCare Foundation.

Edison Pharmaceuticals (Mountain View, CA), a clinical-stage pharmaceutical company developing small molecules to treat mitochondrial disease, closed a $20M Series F financing. Participants include Mitsui & Co. Global Investment.

New Haven Pharmaceuticals (New Haven, CT), a specialty pharmaceutical company focused on a slow release aspirin product, closed a $6.6M Series A. Participants include Connecticut Innovations and private investors.

Kiadis Pharma (Netherlands), a clinical-stage biopharmaceutical company developing treatments for blood cancers, closed a $12.8M Series D financing. Participants include Life Sciences Partners, DFJ-Esprit, Alta Partners, Quest for Growth and NOM.

Synovex (Boston, MA), a clinical stage biotechnology company focused on inhibiting the progression of fibrotic diseases such as arthritis, closed a $3.5M Series C financing. Participants were not identified.

Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Participants include Novartis Venture Fund and H&Q Life Sciences Investors.

Cebix (San Diego, CA), a clinical stage biotechnology company developing a modified insulin C-peptide for the treatment of complications associated with diabetes such as peripheral neuropathy, closed a $30.9M Series B financing. Participants were not identified.

Qinec (United Kingdom), a Health IT company developing tools for web-based medical practice management, closed a $2.5M Series B financing. Participants include Amadeus Capital Partners and Archimedia Investments.

Biophyti (France), a clinical stage pharmaceutical company developing a portfolio of nutraceuticals and drug candidates derived from active natural substances to treat metabolic disorders and age related diseases, closed a $2.6M Series B financing. Participants include Metabrain Research, Seventure Partners and CM-CIC Capital Prive.

Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.

Cardioxyl Pharmaceuticals (Chapel Hill, NC), a clinical stage pharmaceutical company utilizing its proprietary nitroxyl chemistry platform to discover and develop novel therapeutics to treat cardiovascular disease, closed a $28M Series B financing. Participants include OrbiMed Advisors, Osage University Partners, New Enterprise Associates and The Aurora Funds.

« Previous Entries  Next Page »

to top of page...